The STAR Market of the Shanghai Stock Exchange, a Nasdaq-style bourse for pre-revenue startup companies, has rejected one biotech’s application for an initial public offering for the first time since STAR's inception in 2019.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?